Can Keppra (levetiracetam) cause hypotension?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Keppra Cause Hypotension?

Keppra (levetiracetam) can cause hypotension, but this occurs primarily in overdose situations or with rapid intravenous administration; at therapeutic doses, levetiracetam is notably safer than traditional antiepileptic drugs like phenytoin and does not typically cause clinically significant hypotension.

Hypotension Risk in Overdose

Levetiracetam overdose is associated with cardiovascular toxicity including hypotension and bradycardia 1. In a documented case of massive overdose (60-80 g), a patient developed bradycardia, hypotension, and oliguria that transiently responded to atropine and intravenous fluids 1. The mechanism appears to involve levetiracetam acting at muscarinic receptors at high concentrations, as echocardiography showed normal ventricular contractility despite the cardiovascular effects 1.

Another overdose case (30 g ingestion) resulted in respiratory depression and sedation but did not specifically report hypotension as a prominent feature 2. These cases demonstrate that cardiovascular effects are dose-dependent and primarily occur at supratherapeutic levels.

Safety at Therapeutic Doses

Intravenous Administration

  • Rapid IV push is well-tolerated: A study of 213 doses of undiluted 1500 mg IV levetiracetam administered rapidly found only 3 patients (3.8%) experienced hypotension, but all were already receiving vasopressors prior to the dose 3.
  • No hemodynamic instability in ICU patients: A retrospective analysis of 51 critically ill ICU patients receiving levetiracetam reported no adverse hemodynamic events or cardiac arrhythmias 4.
  • Superior to phenytoin: In patients undergoing supratentorial craniotomy, levetiracetam (alone or with lacosamide) caused significantly less blood pressure drop compared to phenytoin during anesthesia (P=0.001 for LEV vs PHT; P≤0.0001 for LEV/LCM vs PHT) 5.

Comparison to Other Antiepileptic Drugs

Levetiracetam is specifically advantageous because it does not cause the hemodynamic instability associated with conventional antiepileptic drugs like phenytoin or benzodiazepines 4. This makes it particularly suitable for critically ill patients where cardiovascular stability is paramount 4.

Clinical Context and Drug Interactions

While levetiracetam itself rarely causes hypotension at therapeutic doses, clinicians should be aware of polypharmacy effects. The European Heart Journal notes that concurrent use of multiple medications with hypotensive potential (beta-blockers, calcium channel blockers, diuretics, central-acting antihypertensives) increases the overall risk of hypotension, particularly in elderly patients 6, 7.

Common Pitfalls to Avoid

  • Do not withhold levetiracetam due to hypotension concerns in patients requiring seizure prophylaxis or treatment, as the cardiovascular safety profile is excellent at therapeutic doses 3, 4.
  • Avoid rapid IV phenytoin instead: If concerned about hypotension during IV antiepileptic administration, phenytoin poses a much greater risk than levetiracetam 5.
  • Adjust for renal function: While not directly related to hypotension, dose adjustment for renal impairment is necessary to prevent accumulation 4.
  • Monitor in overdose situations: If overdose is suspected, prepare for potential cardiovascular support with atropine and IV fluids, as hypotension may occur 1.

References

Research

Cardiovascular toxicity with levetiracetam overdose.

Clinical toxicology (Philadelphia, Pa.), 2016

Research

A case of levetiracetam (Keppra) poisoning with clinical and toxicokinetic data.

Journal of toxicology. Clinical toxicology, 2002

Guideline

Methocarbamol-Induced Hypotension

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.